Stage IV cancer patients who suffer from anxiety may want to
investigate a new research study recently approved by the Food and
Drug Administration (FDA) taking place at specific aim of the study is
to learn whether the psychoactive drug, psilocybin, might be effective
in reducing anxiety, depression and physical pain, and therefore
improving quality of life for Stage IV cancer patients.

Psilocybin is a novel agent that produces a profound alteration in
your state of consciousness. To speak to a patient who went through
this clinical trial, contact David Feuerherd at 310-225-0234. For more
information on the trial, call Charles S. Grob, MD, at 310-222-3175.

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical
Center () is one of the largest independent, not-for-profit biomedical
research institutes in Los Angeles County. Affiliated with both the
David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical
Center, the Institute has an annual budget of over $67 million and
currently supports more than 1,000 research studies in areas such as
cardiology, emerging infections, cancer, women's health, reproductive
health, vaccine research, respiratory physiology, neonatology,
molecular biology, and genetics.

also plays a pivotal role in the training of young physician -
scientists and scientists-to-be and is active in promoting the health
and well being of

http://www.dontplayplay.com/cancer/stage-4-cancer/index.htm

http://www.dontplayplay.com/cancer